Long-term analysis finds disease risk, not remission status, determines transplant outcomes in acute myeloid leukemia

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across Germany, show that the genetic risk of disease, not remission status, determines overall survival of patients with high-risk acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Furthermore,…